Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?

Rigel Pharmaceuticals (RIGL) reported strong H1 2025 commercial performance, with Tavalisse sales up 44% to $68.5 million and Rezlidhia growing 31% to $13.1 million, leading to an increased 2025 revenue guidance of $270-$280 million. The company is also advancing its pipeline, notably R289 in MDS moving to dose expansion, though it faces rising competitive threats from Sanofi's Wayrilz for its ITP franchise and Eli Lilly's Retevmo impacting Gavreto. Despite competitive pressures, RIGL shares have rallied 70.2% year-to-date, trading at a P/S discount to the industry, and are supported by significantly raised analyst EPS estimates for 2025 and 2026.

Analysis

Rigel Pharmaceuticals (RIGL) is demonstrating strong commercial execution, evidenced by a 44% year-over-year increase in Tavalisse sales to $68.5 million and a 31% rise in Rezlidhia sales to $13.1 million in the first half of 2025. This robust top-line growth, augmented by incremental revenues from the newly acquired Gavreto, prompted a significant upward revision of its full-year 2025 revenue guidance to a range of $270-$280 million, a substantial increase from the prior $200-$210 million projection. Beyond its commercial portfolio, the company's pipeline shows promise, with the R289 program for myelodysplastic syndrome (MDS) advancing to a dose expansion phase, with updated data expected later in 2025. However, this positive trajectory is tempered by significant competitive pressures. The recent FDA approval of Sanofi's Wayrilz poses a direct and substantial threat to Rigel's primary revenue source, Tavalisse, particularly given Sanofi's extensive commercial resources. Additionally, Gavreto faces established competition from Eli Lilly's Retevmo. Despite these risks, investor sentiment appears strong, reflected in a 70.2% year-to-date share price rally and a near-doubling of the consensus 2025 EPS estimate over the past 60 days. The stock currently trades at a price-to-sales ratio of 1.94, a discount to both its industry peer group and its historical average.

Key Decisions for Investors

• Given the strong sales momentum, significantly raised revenue guidance, and a valuation discount relative to its peers, investors may view the current share price as an opportunity to gain exposure to continued commercial growth.
• It is critical to closely monitor the market adoption and sales trajectory of Sanofi's Wayrilz, as its commercial success poses a direct and significant threat to the growth of Tavalisse, Rigel's primary revenue driver.
• The upcoming dose escalation data for the R289 program in late 2025 represents a key near-term pipeline catalyst that could materially de-risk the company's long-term growth profile and impact its valuation.